TSPO EXPRESSION IN PATIENTS WITH DIFFERENT CLINICAL AND MORPHOLOGICAL TYPES OF RENAL CELL CARCINOMA
R. A. Zukov , O. K. Polyakova , T. G. Ruksha , Yu. A. Dykhno , T. V. Maksimova
Russian Journal of Oncology ›› 2012, Vol. 17 ›› Issue (1) : 20 -23.
TSPO EXPRESSION IN PATIENTS WITH DIFFERENT CLINICAL AND MORPHOLOGICAL TYPES OF RENAL CELL CARCINOMA
The paper presents the results of an investigation of the expression of peripheral benzodiazepine receptor (TsPO) in patients with renal cell carcinoma in relation to gender, age, disease stage, histological type, and comorbid diseases. In the patients with renal cell carcinoma, the level of TsPO was found to be related to the disease stage, histological type, and the presence of synchronous cancer at other sites. The findings may suggest that TsPO can be used as a marker in predicting the efficiency of treatment and the course of disease.
TsPO / renal cell carcinoma / peripheral benzodiazepine receptor / TsPO / histological types of kidney cancer
| [1] |
Cheville J. S., Lohse C. M., Zincke H. et al. // Am. J. Surg. Pathol. 2003. Vol. 27, N 5. P. 612-624. |
| [2] |
Delahunt B., Eble J. N., McCredie M. R. et al. // Hum. Pathol. 2001. Vol. 32, N 6. P 590-595. |
| [3] |
Everett H., Barry M., Sun X. et al. // J. Exp. Med. 2002. Vol. 196, N 9. P. 1127-1140. |
| [4] |
Galiegue S., Casellas P., Kramar A. et al. // Clin. Cancer Res. 2004. Vol. 10. P. 2058-2064. |
| [5] |
Gavish M., Laor N., Bidder M. et al. // Neuropsychopharmacology. 1996. Vol. 14, N 3. P. 181-186. |
| [6] |
Han Z., Slack R. S., Li W. et al. // J. Recept. Signal Transduct. Res. 2003. Vol. 23, N 2-3. P. 225-238. |
| [7] |
Johnson M. R., Marazziti D., Brawman-Mintzer O. et al. // Biol. Psychiatry. 1998. Vol. 43, N 4. P. 306-309. |
| [8] |
Kurumaji A., Nomoto H., Yamada K. et al. // Am. J. Med. Genet. 2001. Vol. 105, N 2. P. 172-175. |
| [9] |
Lin D., Chang Y. J., Strauss J. F. et al. // Genomics. 1993. - Vol. 18, N 3. P. 643-650. |
| [10] |
Linehan W. M., Zbar B. // Cancer Cell. 2004. Vol. 6. - P. 223-228. |
| [11] |
Maaser K., Grabowski P., Sutter A. P. et al. // Clin. Cancer Res. 2002. Vol. 8. P. 3205-3209. |
| [12] |
Molina A. M., Tickoo S. K., Ishill N. et al. // J. Clin. Oncol. 2009. Vol. 27, N 15S. P. 16017. |
| [13] |
Papadopoulos V., Baraldi M., Guilarte T. R. et al. // Trends Pharmacol. Sci. 2006. Vol. 27, N 8. P. 402-409. |
| [14] |
Patard J.-J., Kim H. L., Lam J. S. et al. // J. Clin. Oncol. 2004. Vol. 22, N 16. P. 3316-3322. |
| [15] |
Patard J.-J., Leray E., Rioux-Leclercq N. et al. // J. Clin. Oncol. 2005. Vol. 23, N 12. P. 2763-2771. |
| [16] |
Pignot G., Elie C., Conquy S. et al. // J. Urology. 2007. Vol. 69, N 2. P. 230-235. |
| [17] |
Ruff M. R., Pert C. B., Weber R. J. et al. // Science. 1985. - Vol. 229. P. 1281-1283. |
| [18] |
Taliani S., Simorini F., Sergianni V. et al. // J. Med. Chem. 2007. Vol. 50, N 2. P. 404-407. |
| [19] |
Veenman L., Gavish M. // Pharmacol. Ther. 2006. Vol. 110, N 3. P. 503-524. |
Eco-Vector
/
| 〈 |
|
〉 |